Jeffrey Friedman

Jeffrey Friedman is an accomplished professional in the biopharmaceutical industry with extensive experience in board governance and investment management. Currently serving as a Board Member at Hillhurst Biopharmaceuticals, Inc. and TRIO Pharmaceuticals, Inc., Friedman is involved in the development of innovative treatments for diseases such as Sickle Cell Disease and cancer. As Managing Partner at Friedman Bioventure, Friedman has been instrumental in identifying and managing investments in the biomedical field since 2012. Previously, contributions were made to various organizations, including PetDx, DTxPharma, and CurePSP, among others. Educational credentials include a Doctor of Medicine and a Doctor of Philosophy in Cancer Biology from Stanford University, complemented by a Pediatric Hematology-Oncology Research Fellowship at Dana Farber Cancer Institute.